The subjects in this study made incongruent naming responses to words and pictures that were presented on alternate trials (e.g., say "car" toBIKE). Their response time was longer if the correct response for the current trial was the name of the stimulus presented on the preceding trial, as compared with a control condition. These results suggest that the tendency to produce the (congruent) name of the stimulus is automatically activated and then inhibited. The "negative priming" effects appeared stronger for words where pictures were primes than for pictures where words were primes. The implications of these results for negative priming and stimulus-response compatibility are discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3758/BF03214556 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pembrolizumab added to neoadjuvant chemotherapy may improve pathological complete response in androgen-receptor positive and low tumor-infiltrating lymphocytes triple-negative breast cancer patients.
Breast Cancer
January 2025
Tepe Prime, MKA Breast Cancer Clinic, 06800, Ankara, Turkey.
A Systematic Literature Review to Determine Gaps in Diagnosing Suspected Infection in Solid Organ Transplant Recipients.
Open Forum Infect Dis
January 2025
Department of Medicine, Division of Infectious Diseases, University of Pittsburgh and UPMC, Pittsburgh, Pennsylvania, USA.
Background: Improved diagnostic testing (DT) of infections may optimize outcomes for solid organ transplant recipients (SOTR), but a comprehensive analysis is lacking.
Methods: We conducted a systematic literature review across multiple databases, including EMBASE and MEDLINE(R), of studies published between 1 January 2012-11 June 2022, to examine the evidence behind DT in SOTR. Eligibility criteria included the use of conventional diagnostic methods (culture, biomarkers, directed-polymerase chain reaction [PCR]) or advanced molecular diagnostics (broad-range PCR, metagenomics) to diagnose infections in hospitalized SOTR.
Elective fertility preservation before and after the Covid-19 pandemic outbreak.
JBRA Assist Reprod
January 2025
Racine IVF Unit, Fertility Institute, Lis Maternity Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Objective: To compare the number and outcomes of elective fertility preservation (FP) before and after the Covid-19 outbreak.
Methods: This retrospective study of 574 women who underwent elective FP between 01/2017-12/2021 included 123 women who underwent the procedure before and 451 who underwent it after the Covid-19 outbreak. The change in the number of women who underwent the procedure each month before and after the pandemic was calculated.
Afatinib and Necitumumab in -Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors.
JTO Clin Res Rep
February 2025
Department of Medicine, Division of Oncology, Stanford University, Stanford, California.
Introduction: Although tyrosine kinase inhibitors (TKIs) are effective against NSCLC harboring sensitizing gene mutations, acquired resistance is inevitable. Preclinical studies suggest that combining EGFR TKI and monoclonal antibody therapies may have activity in mutated NSCLC that has progressed on TKI therapy alone. Therefore, we prospectively evaluated afatinib plus necitumumab in patients with mutated NSCLC.
View Article and Find Full Text PDFClinical and Genomic Features of Androgen Indifferent Prostate Cancer.
Int J Mol Sci
January 2025
Division of Hematology/Oncology, University of Virginia, Charlottesville, VA 22903, USA.
Androgen-indifferent prostate cancer (AIPC) is increasingly common and particularly lethal. Data describing these tumors are sparse, and AIPC remains a poorly understood malignancy. Utilizing the Oncology Research Information Exchange Network (ORIEN) database, we enriched for tumors with features of AIPC using previously described characteristics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!